Förster G, Kahaly G
Klinik und Poliklinik Innere Medizin, Schwerpunkt Endokrinologie und Stoffwechselerkrankungen, Johannes-Gutenberg-Universität Mainz.
Med Klin (Munich). 1998 Jun 15;93(6):365-73. doi: 10.1007/BF03044681.
Ophthalmopathy is the most common extrathyroidal manifestation of Graves' disease, also called thyroid-associated ophthalmopathy.
This autoimmune disorder is characterized by a lymphocyte infiltration of the retrobulbar space. Activated T cells react with the target organ and secrete cytokines, leading to accumulation of glycosaminoglycans, interstitial edema of the peri- and retrobulbar tissue and enlargement of the extraocular muscles. During the inflammatory stage, the increased orbital pressure results in the clinical manifestation of the eye disease.
Thus, therapeutic immunosuppression is often used initially, and by suppressing inflammatory changes, it can result in subjective and objective improvement of the thyroid eye disease. In recent years, new pathogenetic aspects and clinical randomized trials led to modified therapy concepts.
Interdisciplinary management is recommended for rapid diagnosis and effective therapy of patients with thyroid-associated ophthalmopathy.
眼病是格雷夫斯病最常见的甲状腺外表现,也称为甲状腺相关性眼病。
这种自身免疫性疾病的特征是球后间隙淋巴细胞浸润。活化的T细胞与靶器官发生反应并分泌细胞因子,导致糖胺聚糖积聚、眶周和球后组织间质水肿以及眼外肌增大。在炎症阶段,眶压升高导致眼病的临床表现。
因此,治疗性免疫抑制通常最初使用,通过抑制炎症变化,可使甲状腺眼病在主观和客观上得到改善。近年来,新的发病机制方面以及临床随机试验导致了治疗理念的改变。
对于甲状腺相关性眼病患者,建议采用多学科管理以实现快速诊断和有效治疗。